Related references
Note: Only part of the references are listed.HIV-Associated Tuberculosis in Children and Adolescents: Evolving Epidemiology, Screening, Prevention and Management Strategies
Alexander W. Kay et al.
PATHOGENS (2022)
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial
Pablo Rojo et al.
TRIALS (2022)
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
Anna Turkova et al.
LANCET HIV (2022)
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report
Marlotte A. A. van der Veer et al.
ANTIVIRAL THERAPY (2022)
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
A. Turkova et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
Paul Krogstad et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2021)
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
Tom G. Jacobs et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years
Mutsa Bwakura Dangarembizi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2019)
Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study
Helena Rabie et al.
LANCET HIV (2019)
Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen
Retsilisitsoe R. Moholisa et al.
ANTIVIRAL THERAPY (2014)
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial
Diana M. Gibb
LANCET (2013)
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment
J. Mirjam Oudijk et al.
AIDS (2012)
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis
Helen McIlleron et al.
ANTIVIRAL THERAPY (2011)
Blood sample volumes in child health research: review of safe limits
Stephen R. C. Howie
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2011)
Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children
Brookie M. Best et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: A Global Proficiency Testing Program
David Burger et al.
THERAPEUTIC DRUG MONITORING (2011)
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers
CJL la Porte et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography
JAH Droste et al.
THERAPEUTIC DRUG MONITORING (2003)
Share Paper
